Leukemia Therapy – A Look Into the Future
Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
Clinical Interchange™: Improving Outcomes and Overcoming Barriers to Equitable Care in African American Patients With Multiple Myeloma
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Gastrointestinal Malignancies from Paris
2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in Gastrointestinal Cancers
Community Practice Connections™: 19th Annual Meeting of the International Society of Gastrointestinal Oncology®
4th annual Precision Medicine Symposium: An Illustrated Tumor Board
Optimizing Pain Management for Breast Cancer Surgery Patients in the Age of the Opioid Epidemic
FDA Grants Fast Track Designation to RRx-001 for Severe Oral Mucositis in Head and Neck CancerMarch 30th 2023
The FDA has granted a fast track designation to RRx-001 for the prevention and attenuation of severe oral mucositis associated with chemotherapy and radiation in patients with head and neck cancer.
A New Generation of Cytokine-Based Immunotherapy Takes ShapeMarch 30th 2023
Nearly 40 years after the first cytokine-based therapy was approved for the treatment of patients with hairy cell leukemia, investigators are taking a fresh look at ways to leverage these signaling proteins to enhance immunotherapies and vaccines in other cancers.
Amivantamab Provides Long-term Clinical Benefit in Post-Platinum EGFR Exon 20 Insertion+ NSCLCMarch 30th 2023
Amivantamab continued to be tolerable and efficacious in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease progressed on platinum-based chemotherapy.
FDA Grants Full Approval to Pembrolizumab for Select Patients With MSI-H or dMMR Solid TumorsMarch 29th 2023
The FDA has granted full approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability–high or mismatch repair–deficient solid tumors that have progressed following previous treatment and who have no satisfactory alternative options.
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLCMarch 29th 2023
Up-front treatment with osimertinib reduced the risk of brain progression-free survival but provided a comparable overall survival benefit compared with sequential treatment with gefitinib followed by osimertinib in patients with advanced non–small cell lung cancer harboring EGFR mutations.
TALAPRO-2 Data Underscore Potential of Talazoparib Plus Enzalutamide in mCRPCMarch 29th 2023
Neeraj Agarwal, MD, discusses preclinical data that supported the launch of the TALAPRO-2 trial and key efficacy and safety data on the use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer irrespective of homologous recombination repair mutational status.
Dana-Farber Researchers Chart a Course for Understanding, Preventing, and Treating Young-onset Colorectal CancerMarch 29th 2023
Dana-Farber Cancer Institute researchers outline the complexities of colorectal cancer and the research needed to map out a path toward understanding it.
European Commission Approves Cemiplimab Plus Chemotherapy for First-line PD-L1+ NSCLCMarch 29th 2023
The European Commission has approved cemiplimab-rwlc plus platinum-based chemotherapy for the frontline treatment of patients with locally advanced or metastatic PD-L1–positive non–small cell lung cancer without EGFR, ALK, or ROS1 alterations and who are not eligible for chemoradiation.
Severity of Patient-Reported Symptom Burden Remains Low and Stable After Adjuvant Systemic Treatment in CRC
Although some patients with stage II/III colorectal cancer were at an increased risk of severe symptoms and deterioration over time, patient-reported symptoms showed that those with newly diagnosed disease generally reported a low symptom burden that remained stable or improved after receiving adjuvant systemic therapy, according to a retrospective analysis.
Neoadjuvant Olaparib Proves Feasible, Aids Optimal Resection in BRCA-Mutant Ovarian CancerMarch 28th 2023
Neoadjuvant treatment with olaparib prior to surgical resection and adjuvant chemotherapy was well tolerated and led to a 100% optimal resection rate in patients with newly diagnosed, BRCA-mutant ovarian, primary peritoneal, or fallopian tube cancer.
Dostarlimab Plus Chemotherapy Elicits PFS Benefit in Recurrent Endometrial CancerMarch 28th 2023
Dostarlimab plus standard-of-care chemotherapy generated a significant improvement in progression-free survival vs chemotherapy alone for patients with recurrent endometrial cancer, including those with mismatch repair–deficient, microsatellite instability–high tumors.
Pembrolizumab Plus Chemotherapy Improves Survival in dMMR/pMMR Advanced Endometrial CancerMarch 28th 2023
Pembrolizumab plus standard-of-care chemotherapy, followed by maintenance pembrolizumab, reduced the risk of disease progression or death vs chemotherapy alone in patients with mismatch repair–deficient and mismatch repair–proficient advanced or recurrent endometrial cancer.
Fixed-Duration Ibrutinib Plus Venetoclax Earns Approval in Canada for Previously Untreated CLLMarch 28th 2023
Canada Health has approved the fixed-duration, all-oral combination of ibrutinib and venetoclax for the frontline treatment of adult patients with chronic lymphocytic leukemia, including those with 17p deletion.
Obe-cel May Prove a Tolerable Treatment Alternative in Relapsed/Refractory B-ALLMarch 28th 2023
Sameem Abedin, MD, discusses where CAR T-cell therapy falls in the treatment paradigm for B-cell acute lymphoblastic leukemia, the known safety profile of obe-cel as evidenced in early studies, and how findings from the FELIX trial could change the future management of this disease.
Lenvatinib Plus Pembrolizumab Produces Deep, Sustained Responses in Advanced Endometrial CancerMarch 27th 2023
The combination of lenvatinib plus pembrolizumab produced deep, durable tumor responses in both all-comer and mismatch repair–proficient (pMRR) populations of patients with advanced endometrial cancer, according to data from the phase 3 Study 309/KEYNOTE-775 trial.
Ribociclib Plus Endocrine Therapy Meets iDFS End Point in HR+ Early Breast CancerMarch 27th 2023
The combination of ribociclib and endocrine therapy (ET) significantly reduced the risk of disease recurrence vs standard adjuvant ET in patients with hormone receptor–positive/HER2-negative early breast cancer at risk of recurrence.
Trastuzumab Deruxtecan Garners Approval in Japan for HER2-Low Metastatic Breast CancerMarch 27th 2023
Japan’s Ministry of Health, Labor and Welfare has approved fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with HER2-low unresectable or recurrent breast cancer after prior chemotherapy.
Toripalimab Plus Bevacizumab/Chemotherapy Generates Responses in Refractory, Recurrent, or Metastatic Cervical CancerMarch 27th 2023
The combination of toripalimab, bevacizumab, and platinum-based chemotherapy elicited responses in patients with refractory, recurrent or metastatic cervical cancer.